ArticleCNS neuroscience & therapeutics2025
Genetic Associations of Clonal Hematopoiesis With Cardioembolic Stroke: Insights From Genome-Wide Mendelian Randomization, Bulk RNA, Single-Cell RNA Sequencing.
Article in CNS neuroscience & therapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Clonal Hematopoiesis and Risk of Stroke: Evidence From Over 800 000 Individuals Across 3 Cohorts.Stroke · 2026Article
- Mendelian randomization analysis reveals causal associations between HLA gene expression, inflammatory biomarkers, and non-small cell lung cancer risk.Discover oncology · 2026Article
- Causal relationship between metabolic syndrome and gastric cancer: insights from comprehensive analysis and biomarker identification.Translational cancer research · 2026Article
- From trigeminal ganglion to cortex: ATG7 emerges as a key integrator of migraine pathways via multi-omics profiling.The journal of headache and pain · 2025Article
- Genetic Associations of Clonal Hematopoiesis With Cardioembolic Stroke: Insights From Genome-Wide Mendelian Randomization, Bulk RNA, Single-Cell RNA Sequencing.CNS neuroscience & therapeutics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
aimsIschemic stroke (IS), a major global health concern, is associated with aging-related clonal hematopoiesis of indeterminate potential (CHIP), though their mechanistic connection remains unclear. This study explores the causal CHIP-IS relationship, key genetic drivers, and potential therapies.
methodsGenetic markers for CHIP were selected as instrumental variables and analyzed through bidirectional two-sample Mendelian randomization (MR) using GWAS data from IS cohorts. Functional annotation of significant loci was performed via FUMA, while transcriptomic datasets from GEO underwent differential expression analysis, weighted gene co-expression network construction, and machine learning-driven biomarker discovery. Protein-protein interaction networks and single-cell RNA sequencing (scRNA-seq) were employed to elucidate cellular mechanisms.
resultsMR analysis revealed a significant causal association between CHIP and cardioembolic stroke (CES) risk (OR = 70.15, 95% CI = 2.03-2428.52, p = 0.02). PARP1 and CD3G emerged as hub genes connecting CHIP to IS pathogenesis, validated through multi-omics integration. Fourteen feature genes were identified, and potential therapeutic drugs targeting this pathway were discovered. scRNA-seq analysis further demonstrated downregulation of CD3G in T cells post-IS, disrupting immune cell communication and differentiation.
conclusionThis study provides robust genetic evidence for CHIP-mediated predisposition to CES and identifies PARP1 and CD3G as critical therapeutic targets. The integration of machine learning and single-cell genomics offers novel insights into immune dysregulation in IS, paving the way for precision prevention strategies in CHIP patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.